Funding of the Development Program Sample Clauses

Funding of the Development Program. 3.1 Kos shall provide total funding for Phase 1 of the Development Program as set forth in Appendix B, in the amount of **************************** ****************************************************************************** ******************* of which shall be paid to Fuisz within *********** days of the Effective Date, and ******************************** of which shall be paid within ************************ following the end of Phase 1 and ****************************************** of which shall be paid within **************** following completion of the Phase 1 ******************* of Appendix B. This amount of funding may be increased by mutual agreement. This funding shall not include the cost of the ******************* which shall be funded and paid for ************. In the event Kos chooses to proceed to Phase 2 and/or Phase 3 as set forth in Appendix B, unless Fuisz determines further development is not feasible, Kos shall pay to Fuisz additional amounts commensurate with the activity involved and as mutually agreed, consistent with the cost of Phase 1 and with the level of activity, for Phase 2 and for Phase 3 payable within **************** of commencement of the phases.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Funding of the Development Program. (a) First-Time Pre-Clinical Development Activities. Alexion shall bear [*] percent ([*]%), and XOMA shall bear [*] percent ([*]%), of all Development Expenses incurred in conducting each activity set forth in the Initial Development Plan for the first Product to undergo such activity (collectively, the "First-Time Pre-Clinical Development Activities").
Sample 1Sample 2Sample 3See All (5)
Funding of the Development Program. (a) In consideration of the royalty payments set forth in Section 2 of this Agreement, Crescendo hereby agrees to fund the Elmiron -Registered Trademark- Development Program in amounts as proposed by ALZA and approved by Crescendo from time to time (the "Development Payments"). The Elmiron -Registered Trademark- Development Program shall be set forth in work plans prepared by ALZA which are subject to the approval (in whole or in part) or the rejection (in whole or in part) of Crescendo. Each such approved work plan shall constitute a "Work Plan" within the meaning of the Development Agreement. The parties agree to review the Work Plan from time to time (no less often than the end of each stage of development) and to revise the Work Plan as appropriate so that it remains a best estimate of the work to be done under the Elmiron -Registered Trademark- Development Program and the amounts required to fund such work. Crescendo shall not be obligated to make Development Payments in excess of those provided for in an approved Work Plan, and ALZA shall not be obligated to perform work on the Elmiron -Registered Trademark- Development Program which would result in Development Payments exceeding those in an approved Work Plan.
Sample 1Sample 2See All (5)
Funding of the Development Program. Confidential information omitted and filed with the Commission
Sample 1Sample 2
Funding of the Development Program. Except as otherwise agreed by the Parties, Allergan shall bear all of the costs incurred in connection with the Development Program.
Sample 1Sample 2
Funding of the Development Program. In consideration of Third Wave's performance of its obligations under the Development Program, Endogen will fund Third Wave's development of the Quantitation Kits and Human Probe Panels to a maximum of $1,050,000 over the thirty-six month period from December 1, 1997 based upon the schedule of headcount estimates and workload sharing between the Parties attached hereto as Schedule 5.3.A. The amounts payable to Third Wave shall be equal to the lesser of (i) [CONFIDENTIAL TREATMENT REQUESTED]* and (ii) the amounts set forth on Schedule 5.3.B attached hereto. As set forth in Schedule 5.3.B, for each Development Year, Endogen shall make four equal payments of a maximum of [CONFIDENTIAL TREATMENT REQUESTED]*, to be paid quarterly in advance by the twentieth (20th) business day of the calendar month of each calendar quarter (e.g., January 20th, April 20th, July 20th, and October 20th), pro rated as necessary for the first and last quarters. Such quarterly payments shall be -------------------- *[CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL WHICH HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. based on Third Wave's good faith estimates of its Development Expenditures for the current Development Year (which estimates shall be provided to Endogen at least ninety (90) days prior to the commencement of a Development Year, provided, however, that with respect to the first Development Year, (i) Endogen's first quarterly payment shall be pro rated to [CONFIDENTIAL TREATMENT REQUESTED]* and shall be payable on or before December 1, 1997, and (ii) Third Wave's good faith estimates of its Development Expenditures for the first Development Year shall be provided to Endogen on or before September 30, 1997. Any amounts paid by Endogen and not used in accordance with this Section 5.3 shall be credited against the following quarterly payment, any underpayment of a quarterly payment by Endogen based upon Third Wave's actual Development Expenditures shall be paid with the next quarterly payment upon invoices by Third Wave. In the event that during any quarter of a Development Year the amount due by Endogen to Third Wave pursuant to this Section is less than the amount proscribed on Schedule 5.3.B, the difference may be carried forward to future quarters within that Development Year to increase the ...
Sample 1
Funding of the Development Program. 4.4.1 During the TERM of the DEVELOPMENT PROGRAM, AvP shall assume full responsibility for paying the budgeted DEVELOPMENT PROGRAM costs set forth in the applicable PROGRAM Plan and Budget, except for costs that are required for activities in the DEVELOPMENT PROGRAM if these activities are required only for the CRUCELL TERRITORY and not for the AvP TERRITORY.
Sample 1
AutoNDA by SimpleDocs
Funding of the Development Program. (a) In consideration of the royalty payments set forth in Section 2 of this Agreement, Crescendo hereby agrees to fund the Doxil Development Program in amounts as proposed by ALZA and approved by Crescendo from time to time (the "Development Payments").
Sample 1
Funding of the Development Program 
Sample 1Sample 2Sample 3See All (4)

Related to Funding of the Development Program

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Development Funding (a) Viewray will pay 3D Line the then U.S. Dollar equivalent of €[***] within three (3) days of the Effective Date for the engineering services required to develop/ deliver the Deliverable described in Section 2.1(a)(i).

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Research Funding Genocea shall pay to Isconova in total [* * *] payable as follows: (i) $[* * *] in equal monthly installments for each remaining month in 2009 following the Effective Date and (ii) $[* * *] in equal monthly installments during the period from January 1, 2010 until March 31, 2012. The Research Funding shall be used solely for the performance of activities under the Research and Phase 1 Supply Plan and the Development and Scale-Up Plan and, for the avoidance of doubt, solely to fund Development and research activities for human (and not veterinary) applications in accordance with such Research and Phase 1 Supply Plan and Development and Scale-Up Plan. Notwithstanding anything to the contrary above, the Parties agree that this restriction shall only apply to the allocation and use of the Research Funding as such, and shall not be construed as limiting or affecting the ownership of any Isconova Technology and Joint Technology created, conceived, reduced to practice or Invented hereunder. Isconova’s ownership and/or rights to the Isconova Technology and Joint Technology shall exclusively be governed by the provisions in Section 3.3. and Isconova’s use of the Isconova Technology and Joint Technology shall be subject only to the licenses granted to Genocea in Sections 3.1.1 through 3.1.3. Isconova shall during the Research Term allocate not less than two (2) dedicated FTEs for Isconova’s research work for Genocea hereunder and each such dedicated FTE shall be paid through Research Funding. During the Research Term, Isconova shall, within fifteen (15) days after the end of each month, deliver to Genocea a report setting forth the number of Isconova FTEs that worked on activities under the Development and Scale-Up Plan and the Research and Phase 1 Supply Plan, as well as other costs and expenses of Isconova evidencing recourses spent on Isconova’s research work hereunder. Researching Funding THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. payments shall be made within fifteen (15) days after the end of each calendar month.

  • Investment Program The Subadviser is hereby authorized and directed and hereby agrees, subject to the stated investment objective and policies of the Fund as set forth in the Trust’s current Registration Statement and subject to the supervision of the Adviser and the Board of Trustees of the Trust, to (i) develop and furnish continuously an investment program and strategy for the Fund in compliance with the Fund’s investment objective and policies as set forth in the Trust’s current Registration Statement, (ii) provide research and analysis relative to the investment program and investments of the Fund, (iii) determine (subject to the overall supervision of the Board of Trustees of the Trust) what investments shall be purchased, held, sold or exchanged by the Fund and what portion, if any, of the assets of the Fund shall be held in cash or cash equivalents, and (iv) make changes on behalf of the Trust in the investments of the Fund. In accordance with paragraph 2(ii)(b), the Subadviser shall arrange for the placing of all orders for the purchase and sale of securities and other investments for the Fund’s account and will exercise full discretion and act for the Trust in the same manner and with the same force and effect as the Trust might or could do with respect to such purchases, sales or other transactions, as well as with respect to all other things necessary or incidental to the furtherance or conduct of such purchases, sales or transactions. The Subadviser will make its officers and employees available to meet with the Adviser’s officers and directors on due notice at reasonable times to review the investments and investment program of the Fund in light of current and prospective economic and market conditions. The Subadviser is authorized on behalf of the Fund to enter into agreements and execute any documents required to make investments pursuant to the Prospectus as may be amended from time to time. The Subadviser’s responsibility for providing portfolio management services hereunder shall be limited to only those assets of the Fund which the Adviser determines to allocate to the Subadviser (those assets being referred to as the “Fund Account”), and the Subadviser agrees that it shall not consult with any investment advisor(s) (within the meaning of the 0000 Xxx) to the Fund or any other registered investment company or portfolio series thereof under common control with the Fund concerning transactions for the Fund Account in securities or other assets such that the exemptions under Rule 10f-3, Rule 12d-3 and/or Rule 17a-10 under the 1940 Act would not be available with respect to the Fund. The Subadviser shall exercise voting authority with respect to proxies that the Fund is entitled to vote by virtue of the ownership of assets attributable to that portion of the Fund for which the Subadviser has investment management responsibility; provided that the exercise of such authority shall be subject to periodic review by the Adviser and the Trustees of the Trust; provided, further that such authority may be revoked in whole or in part by the Adviser if required by applicable law. The Subadviser shall exercise its proxy voting authority hereunder in accordance with such proxy voting policies and procedures as the Trust may designate from time to time. The Subadviser shall provide such information relating to its exercise of proxy voting authority hereunder (including the manner in which it has voted proxies and its resolution of conflicts of interest) as reasonably requested by the Adviser from time to time. In the performance of its duties hereunder, the Subadviser is and shall be an independent contractor and except as expressly provided for herein or otherwise expressly provided or authorized shall have no authority to act for or represent the Fund or the Trust in any way or otherwise be deemed to be an agent of the Fund, the Trust or of the Adviser. If any occasion should arise in which the Subadviser gives any advice to its clients concerning the shares of a Fund, the Subadviser will act solely as investment counsel for such clients and not in any way on behalf of the Trust or the Fund.

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

Time is Money Join Law Insider Premium to draft better contracts faster.